Drug profile · INN
bendamustine hydrochloride
TREAKISYM PARTIAL CHANGE APPROVAL
bendamustine hydrochloride (TREAKISYM PARTIAL CHANGE APPROVAL) is a dna inhibitor. Route of administration: iv (infusion). Current US regulatory status: approved.
Drug details — bendamustine hydrochloride
- US status
- approved
- Class
- —
- Route
- IV (INFUSION)
- Patents
- 2
- Programs
- 14
- Data quality
- 0.84
Quick answer
bendamustine hydrochloride (TREAKISYM PARTIAL CHANGE APPROVAL) is a dna inhibitor. Route of administration: iv (infusion). Current US regulatory status: approved.
Key facts
Mechanism of action
DNA inhibitor
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is bendamustine hydrochloride?
bendamustine hydrochloride (TREAKISYM PARTIAL CHANGE APPROVAL) is a dna inhibitor. Route of administration: iv (infusion). Current US regulatory status: approved.
What is the brand name for bendamustine hydrochloride?
TREAKISYM PARTIAL CHANGE APPROVAL is a marketed brand name for bendamustine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bendamustine hydrochloride?
bendamustine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.